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Introduction: Rheumatoid arthritis (RA) is a complex polygenic inflammatory disease associated with accelerated
atherosclerosis and increased cardiovascular (CV) disease risk. Interferon regulatory factor 5 (IRF5) is a regulator of
type I interferon induction. Recently, researchers have described an association between multiple single-nucleotide
polymorphisms of the IRF5 gene and some rheumatic disorders. In this study, we aimed to evaluate whether three
different haplotype blocks within the IRF5 locus which have been shown to alter the protein function are involved
in the risk of CV events occurring in Spanish RA patients.
Methods: Three IRF5 polymorphisms (rs2004640, rs2070197 and rs10954213) representative of each haplotype
group were genotyped by performing TaqMan assays using a 7900HT Fast Real-Time PCR System with tissue from a
total of 2,137 Spanish patients diagnosed with RA. Among them, 390 (18.2%) had experienced CV events. The
relationship of IRF5 genotypes and haplotypes to CV events was tested using Cox regression.
Results: Male sex, age at RA diagnosis and most traditional risk factors (hypertension, dyslipidemia and smoking
habit) were associated with increased risk for CV events in the RA population. Interestingly, a protective effect of
both IRF5 rs2004640 GG and IRF5 rs10954213 GG genotypes against the risk for CV events after adjusting the results
for sex, age at RA diagnosis and traditional CV disease risk factors was observed (hazard ratio (HR) = 0.6, 95%
confidence interval (CI) = 0.38 to 0.92, P = 0.02; and HR = 0.58, 95% CI = 0.36 to 0.95, P = 0.03, respectively). Moreover,
we detected a protective effect of the GTG haplotype against the risk for CV events after adjusting the results for
potential confounding factors (HR = 0.72, 95% CI = 0.56 to 0.93, P = 0.012).
Conclusions: Our results reveal that IRF5 gene variants are associated with risk of CV events in patients with RA.* Correspondence: miguelaggay@hotmail.com
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Table 1 Demographic and clinical characteristicsa
Clinical features % (n/N) or mean ± SD
Patients 2,137
Main characteristics
Age at disease onset (yr) 53 ± 14.8
Follow-up duration (yr) 12.5 ± 8.25
Females (%) 75.1
Rheumatoid factor–positiveb 68.3 (1,413/2,070)
Anti-CCP antibody–positive 57.3 (1,024/1,785)
Shared epitope–positive 62.6 (734/1,173)
Erosions 54.4 (866/1,591)
Extraarticular manifestationsc 31.3 (481/1,537)
Cardiovascular risk factors
Hypertension 40.3 (846/2,100)
Diabetes mellitus 13.1 (275/2,100)
Dyslipidemia 38.3 (805/2,100)
Obesity 19.6 (413/2,100)
Smoking habit 27.4 (576/2,100)
Patients with cardiovascular events (total) 18.2 (390/2,137)
Ischemic heart disease 8.5 (181/2,137)
Heart failure 5.7 (122/2,137)
Cerebrovascular accident 5.6 (120/2,137)
Peripheral arteriopathy 2.8 (60/2,137)
aCCP: Cyclic citrullinated peptide; SD: Standard deviation. bAt least two
determinations were required for analysis of this result. cExtraarticular
manifestations of disease (if RA patients had at least one of the following
manifestations: nodular disease: Felty’s syndrome, pulmonary fibrosis,
rheumatoid vasculitis, secondary Sjögren’s syndrome) [4].
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Rheumatoid arthritis (RA) is a chronic inflammatory
rheumatic disease associated with an increased risk for
cardiovascular (CV) events and CV disease–related deaths
compared to the general population [1]. Because of that,
adequate stratification of CV disease risk has special rele-
vance in RA patients. Researchers in several studies have
demonstrated that RA is an independent risk factor for
premature heart disease [2]. This process is the result of a
combined effect of traditional CV disease risk factors [3],
the magnitude and severity of a chronic inflammatory re-
sponse [4] and genetic factors located inside [4] and out-
side the human leukocyte antigen (HLA) region [5-8].
Type I interferons (IFNs) are signaling molecules in-
volved in both innate and adaptive immunity. Misregu-
lated expression of type I IFN genes has been observed
in peripheral white blood cells of patients with several
autoimmune diseases [9]. In this regard, interferon regu-
latory factor 5 (IRF5) has been involved in the regulation
of type I IFN gene transcription [10,11]. This protein is
critical for the production of proinflammatory cytokines
[12], such as TNF-α, interleukin 12 (IL-12) and IL-6,
following Toll-like receptor signaling. IRF5 also acts as
a molecular switch that controls inflammatory mecha-
nisms mediated by macrophage cells [12].
IRF5 protein is encoded by the IRF5 gene, which is lo-
cated in chromosome 7q32.1. Several genetic studies have
described the relevance of multiple single-nucleotide poly-
morphisms (SNPs) of the IRF5 gene in different rheumatic
disorders, such as RA and lupus erythematosus [13,14]. In
this context, three groups of correlated IRF5 variants, des-
ignated as groups 1, 2 and 3, have been found to be inde-
pendently associated with these inflammatory disorders
and with different functional roles. Group 1 includes SNPs
tagging a 30-bp in-frame insertion/deletion variant of exon
6 that alters protein stability. The association of group
2 SNPs seems to be explained by the T allele of IRF5
rs2004640 polymorphism that allows the expression of an
alternative isoform and is associated with significantly
higher levels of IRF5 expression. The association of group
3 SNPs is probably due to the rs10954213 A allele that
creates an early polyadenylation site which leads to higher
IRF5 expression [14].
Taking into account all of these considerations to-
gether in the present study, we analyzed the potential
role of one tagging SNP of each group of independent
signals (rs2004640, rs2070197 and rs10954213) in the
risk for CV disease in a large and well-characterized co-
hort of patients with RA.
Methods
Patients and study protocol
A set of 2,137 Spanish patients with RA were included
in the present study. Blood samples were obtained frompatients recruited from University Hospital Lucus Augusti
(Lugo), Marqués de Valdecilla University Hospital
(Santander), Hospital de Bellvitge (Barcelona) Hospital
Clínico San Carlos, La Paz University Hospital, Hospital de
La Princesa, University Hospital Gregorio Marañón and 12
de Octubre University Hospital (Madrid). Informed writ-
ten consent was obtained from all participants. The study
was approved by the ethics committees of Galicia for
University Hospital Lucus Augusti; of Cantabria for
Marqués de Valdecilla University Hospital; of Cataluña for
Hospital de Bellvitge; and of Madrid for Hospital Clínico
San Carlos, La Paz University Hospital, Hospital de La
Princesa, University Hospital Gregorio Marañón and 12
de Octubre University Hospital. All the patients fulfilled
the RA classification criteria published by the American
College of Rheumatology in 1987 and 2010 [15,16]. In all
the cases, patients were assessed for the IRF5 rs2004640,
rs2070197 and rs10954213 polymorphisms.
Data on the main demographic data, clinical character-
istics, CV disease risk factors and CV events of patients
enrolled in the study are shown in Table 1. Three hun-
dred ninety (18.2%) of the patients had experienced CV
events. Definitions of CV events and traditional CV
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scribed [4,17].
Genotyping
Patient DNA was obtained from peripheral blood using
standard methods. The IRF5 rs2004640, rs2070197 and
rs10954213 polymorphisms were genotyped with prede-
signed TaqMan SNP genotyping assays in a 7900HT Fast
Real-Time PCR System according to the conditions recom-
mended by the manufacturer (Applied Biosystems, Foster
City, CA, USA). Negative controls and duplicate samples
were included to check the accuracy of genotyping.
Statistical analysis
The genotype data were checked for deviation from
Hardy-Weinberg equilibrium (HWE) using a previously
described method [18]. The relationship of genotypes, al-
leles and haplotypes to CV events that occurred in the
follow-up was tested using Cox regression adjusted for sex,
age at RA diagnosis and traditional CV disease risk factors.
For that purpose, we used the most frequent genotype, al-
lele and haplotype as reference variables. The end of
follow-up was the first date of occurrence of the following:
end of the study period, date of death or date of CV event.
Follow-up time was estimated as the difference between
the RA diagnosis date and the end of follow-up. Patients
without CV events during the follow-up time and those
who died by any non–CV-event–related cause were cen-
sored. The results are expressed as hazard ratios (HRs)
with 95% confidence intervals (CIs). In order to have aTable 2 Factors associated with cardiovascular events in a ser
Variables H
Males (reference: females) 1.















aCI: Confidence interval; HR: Hazard ratio; RA: Rheumatoid arthritis. bP-values estima
rheumatoid arthritis diagnosis and traditional cardiovascular disease risk factors (hyreference population, 10,000 replications were generated
by assigning CV events in randomized fashion to the ac-
tual studied population. The proportion of the risk for CV
disease due to age at disease diagnosis, smoking history,
hypertension and genetic variants at the IRF5 locus among
the RA patients was estimated as the Nelson-Aalen cumu-
lative HR. Comparative values between the different gen-
etic models of inheritance for IRF5 polymorphisms were
estimated using the Akaike Information Criterion (AIC).
Statistical significance was defined as P ≤ 0.05, and all ana-
lyses were performed using Stata SE/12 statistical software
(Stata Corp, College Station, TX, USA).
Results
The IRF5 rs2004640, rs2070197 and rs10954213 poly-
morphism genotype distributions were in Hardy-Weinberg
equilibrium. The genotyping success rate was greater than
98% in all cases. Genotype and allele frequencies of the
IRF5 rs2004640, rs2070197 and rs10954213 polymor-
phisms were in agreement with the data in the HapMap
database [19].
Table 2 describes those factors that were associated
with the risk of CV disease in our cohort of RA patients.
As expected, sex and most of the traditional CV disease
risk factors (hypertension, dyslipidemia and smoking
habit) were associated with increased risk of CV events
(P < 0.05 in all cases) (Table 2). Interestingly, when we
analyzed the IRF5 rs2004640, rs2070197 and rs10954213
polymorphisms separately, we observed a protective ef-
fect of the IRF5 rs2004640 GG genotype against the riskies of 2,137 rheumatoid patientsa
R (95% CI) P-values P-valuesb
42 (1.07 to 1.87) 0.015
07 (1.06 to 1.09) <0.001
40 (1.029 to 1.92) 0.032
18 (0.83 to 1.68) 0.344
93 (0.67 to 1.31) 0.702
42 (1.05 to 1.93) 0.022
58 (1.26 to 1.99) <0.001
(reference) – –
07 (0.79 to 1.45) 0.664 0.670
59 (0.38 to 0.92) 0.020 0.034
(reference) – –
16 (0.69 to 1.95) 0.58 –
32 (0.32 to 5.52) 0.39 –
(reference) – –
95 (0.71 to 1.26) 0.73 0.738
58 (0.36 to 0.95) 0.03 0.049
ted on the basis of 10,000 replications. cAdjusted for sex, age at time of
pertension, diabetes mellitus, dyslipidemia, obesity, smoking habit).
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diagnosis and traditional CV disease risk factors (hyperten-
sion, diabetes mellitus, dyslipidemia, obesity and smoking
habit) (HR = 0.6, 95% CI = 0.38 to 0.92, P = 0.02) (Table 2).
Additionally, the risk of CV disease was decreased in the
group of RA patients who carried the IRF5 rs10954213
GG genotype after we adjusted the results for potential
confounders (HR = 0.58, 95% CI = 0.36 to 0.95, P = 0.03)
(Table 2). These results were also significant after we esti-
mated by simulation (P = 0.034 and P = 0.049 for the IRF5
rs2004640 GG and rs10954213 GG genotypes, respect-
ively) (Table 2). However, we found no statistically signifi-
cant differences when we assessed the IRF5 rs2070197
polymorphism according to the presence or absence of
CV events (Table 2).
In a further step, we combined the three polymor-
phisms to create haplotypes (Table 3). As shown in
Table 3, we detected a protective effect of the GTG
haplotype after adjusting the results for sex, age at RA
diagnosis and traditional CV disease risk factors (HR =
0.72, 95% CI = 0.56 to 0.93, P = 0.012).
Additional file 1: Table S1 describes the proportion of
the CV disease risk disease for RA patients due to age at
disease diagnosis, smoking history, hypertension and the
genetic variants at the IRF5 locus. Additional file 2: Table
S2 displays the genetic model of inheritance of our analysis.
Interestingly, as shown in Additional file 1: Table S1, the
presence of GG genotypes in the IRF5 rs2004640 and
rs1095213 polymorphisms decreased CV disease risk in
0.7% and 1% of patients, respectively (Additional file 1:
Table S1). In addition, smoking, age at disease diagnosis
and presence of hypertension increased the risk of CV
disease (Additional file 1: Table S1). Further, as shown in
Additional file 2: Table S2, the AIC estimation for the reces-
sive model showed the lower level in the IRF5 rs2004640
and rs1095213 polymorphisms, which made it the prefera-
ble model for our study (Additional file 2: Table S2).
Discussion
CV disease is the most common cause of premature
mortality in patients with RA [1,2]. The augmented CVTable 3 Results of haplotype analysis in rheumatoid
arthritis patients with vs. without cardiovascular diseasea
Haplotypes HR (95% CI)b P-valueb
rs2004640 rs2070197 rs10954213
T T A 1 (reference) –
G T G 0.72 (0.56 to 0.93) 0.012
G T A 0.85 (0.61 to 1.18) 0.34
T C A 1.14 (0.75 to 1.74) 0.52
aCI: confidence interval; HR: hazard ratios. bAdjusted for sex, age at time of
rheumatoid arthritis diagnosis and traditional cardiovascular disease risk
factors (hypertension, diabetes mellitus, dyslipidemia, obesity and
smoking habit).disease mortality observed in this pathology is the result
of a compound effect mediated by traditional CV disease
risk factors and chronic inflammation [3,4]. Because
genes have also been associated with an increased risk of
CV disease in RA, research in the past several years has
been focused on the search for genetic markers that may
improve the identification of RA patients at risk of ex-
periencing CV events [4-8].
Outside the HLA region, IFN pathway genes, which
encode cytokines with critical modulatory effects on in-
nate and adaptive immunity, have been shown to repre-
sent a key component of the genetic network leading to
autoimmune processes. In this context, several polymor-
phisms in the IRF5 gene (a regulator of type I IFN in-
duction) [10,11] are associated with an increased risk of
immune-mediated diseases [13,14]. Because of that, in
this study we analyzed three genetic variants (IRF5
rs2004640, rs2070197 and rs10954213) as representa-
tives of three different IRF5 haplotype blocks [14]. To
the best of our knowledge, our study constitutes the
largest series of RA patients assessed for the potential
influence of IRF5 polymorphisms in the risk of CV dis-
ease. Interestingly, when we studied each of the poly-
morphisms separately, our results revealed a protective
effect of the IRF5 rs2004640 GG and IRF5 rs10954213
GG genotype variants against the risk of CV events in
RA. Moreover, when we analyzed all the genetic variants
together to create haplotypes, our results revealed a pro-
tective effect of the GTG haplotype (the one that carries
both G alleles of IRF5 rs2004640 and rs10954213 polymor-
phisms) against the risk of CV disease. Because the pro-
tective effect of the mutant allele of the IRF5 rs2004640
and rs1095213 polymorphisms is seen only in homozygo-
sis, we can conclude that our study is adjusted to a reces-
sive model of inheritance. Additionally, the results derived
from our study are in accordance with those obtained in
other pathologies [20,21]. In this context, the results of a
recent study of individuals diagnosed with RA revealed an
association between the IRF5 rs2004640 polymorphism
and subclinical atherosclerosis [22].
The results obtained in this study provide additional evi-
dence on the potential role that genetic factors may play
in the development of CV disease in RA. The search for
genetic markers associated with CV disease in RA may be
important to establishing a better characterization of RA
patients at risk of CV disease. Improved understanding of
these underlying genetic may be useful to establish future
therapeutic targets to decrease the risk of CV disease in
RA patients.Conclusion
Our results reveal that IRF5 gene variants are associated
with CV disease in RA patients.
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